Jerome D. Jabbour J.D.
Net Worth

Last updated:

What is Jerome D. Jabbour J.D. net worth?

The estimated net worth of Mr. Jerome D. Jabbour J.D. is at least $6,631,715 as of 17 Mar 2020. He owns shares worth $1,381,715 as insider and has received compensation worth at least $5,250,000 in Matinas BioPharma Holdings, Inc..

What is the salary of Jerome D. Jabbour J.D.?

Mr. Jerome D. Jabbour J.D. salary is $750,000 per year as Co-Founder, Chief Executive Officer, Pres & Director in Matinas BioPharma Holdings, Inc..

How old is Jerome D. Jabbour J.D.?

Mr. Jerome D. Jabbour J.D. is 51 years old, born in 1974.

What stocks does Jerome D. Jabbour J.D. currently own?

As insider, Mr. Jerome D. Jabbour J.D. owns shares in one company:

Company Title Shares Price per share Total value
Matinas BioPharma Holdings, Inc. (MTNB) Co-Founder, Chief Executive Officer, Pres & Director 799,511 $1.73 $1,381,715

What does Matinas BioPharma Holdings, Inc. do?

Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. It develops products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nano-crystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is LYPDISO, a prescription-only omega-3 free fatty acid-based composition intended for the treatment of cardiovascular and metabolic conditions. The company also offers MAT2203, an oral formulation of amphotericin B that is in Phase II clinical trials for the prevention of invasive fungal infections due to immunosuppressive therapy in patients. In addition, it provides MAT2501, an orally administered formulation of the broad-spectrum aminoglycoside antibiotic amikacin that has completed Phase I clinical trials to treat various types of multidrug-resistant bacteria, including non-tuberculous mycobacterium infections, as well as various multidrug-resistant gram negative and intracellular bacterial infections. Matinas BioPharma Holdings, Inc. has a research collaboration with the National Institute of Allergy and Infectious Diseases for the development of Gilead's antiviral remdesivir; and a feasibility collaboration with Genentech, Inc. for the development of oral formulations. The company was incorporated in 2013 and is based in Bedminster, New Jersey.

Jerome D. Jabbour J.D. insider trading

Matinas BioPharma Holdings, Inc.

Transaction Date Security Shares Price per share Total value Source
Purchase
Common Stock, par value $0.0001 per share 10,000 N/A N/A
Purchase
Common Stock, par value $0.0001 per share 14,650 N/A N/A
Purchase
Common Stock, par value $0.0001 per share 12,487 $0.8 $9,977
Purchase
Series B Convertible Preferred Stock 15 $0.5 $8

Matinas BioPharma Holdings key executives

Matinas BioPharma Holdings, Inc. executives and other stock owners filed with the SEC: